BindingDB logo
myBDB logout

18 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
26183543 87 Discovery of potent and selective nonplanar tankyrase inhibiting nicotinamide mimics.EBI University of Oulu
26026769 24 Structure-based design, synthesis and evaluation in vitro of arylnaphthyridinones, arylpyridopyrimidinones and their tetrahydro derivatives as inhibitors of the tankyrases.EBI University of Bath
26061013 55 Tankyrase 1 Inhibitors with Drug-like Properties Identified by Screening a DNA-Encoded Chemical Library.EBI £Philochem AG
25847770 4 Structure-activity relationship and properties optimization of a series of quinazoline-2,4-diones as inhibitors of the canonical Wnt pathway.EBI Sienabiotech S.p.A.
25680029 12 Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.EBI The Institute of Cancer Research
24527792 8 Design, synthesis, crystallographic studies, and preliminary biological appraisal of new substituted triazolo[4,3-b]pyridazin-8-amine derivatives as tankyrase inhibitors.EBI Universit£ degli Studi di Perugia
23574272 30 Screening and structural analysis of flavones inhibiting tankyrases.EBI University of Oulu
23473363 12 Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.EBI Oslo University Hospital
23316926 12 Discovery of a class of novel tankyrase inhibitors that bind to both the nicotinamide pocket and the induced pocket.EBI Amgen Inc.
22233320 19 Structural basis of selective inhibition of human tankyrases.EBI Abo Akademi University
22260203 73 [1,2,4]triazol-3-ylsulfanylmethyl)-3-phenyl-[1,2,4]oxadiazoles: antagonists of the Wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding.EBI Novartis Institutes for Biomedical Research
20565110 7 Structural basis for the interaction between tankyrase-2 and a potent Wnt-signaling inhibitor.EBI Karolinska Institutet
19654408 2521 AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).EBI Ambit Biosciences